Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Genmab A/S (OTCMKTS:GNMSF) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 61,100 shares, a decline of 23.5% from the February 13th total of 79,900 shares. Based on an average trading volume of 300 shares, the short-interest ratio is currently 203.7 days. Approximately 0.1% of the company’s shares are short sold.

Genmab A/S Price Performance

GNMSF traded up $11.07 during midday trading on Monday, reaching $208.89. 427 shares of the company’s stock traded hands, compared to its average volume of 3,166. The firm has a fifty day moving average of $211.21 and a two-hundred day moving average of $222.86. The stock has a market capitalization of $13.80 billion, a price-to-earnings ratio of 11.92 and a beta of 1.08. Genmab A/S has a 52 week low of $186.61 and a 52 week high of $310.56.

Genmab A/S (OTCMKTS:GNMSF) last released its quarterly earnings results on Wednesday, February 12th. The company reported $5.70 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.